• Context Therapeutics posted a net loss of USD 8.68 million for the three months ended March 31, 2026, widening 90% year over year.
• Operating loss widened 69% to USD 9.34 million as research and development expense more than doubled to USD 7.02 million.
• General and administrative expense rose 13% to USD 2.33 million, while interest income fell 46% to USD 520,139.
• Cash and cash equivalents totaled USD 54.5 million, expected to fund operations into mid-2027.
• FDA granted Fast Track designation to CTIM-76 on April 2, 2026, with Phase 1a interim data expected in June for CTIM-76 and September for CT-95; CT-202 cleared Australian ethics and trial notification steps with first dosing expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-031267), on May 06, 2026, and is solely responsible for the information contained therein.